Literature DB >> 16356834

Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.

Vasil F Chekhun1, Galina I Kulik, Olga V Yurchenko, Volodymyr P Tryndyak, Igor N Todor, Liliana S Luniv, Nadiya A Tregubova, Tamara V Pryzimirska, Beverly Montgomery, Nataliya V Rusetskaya, Igor P Pogribny.   

Abstract

The resistance of cancer cells to chemotherapeutic agents is a major clinical problem and an important cause of treatment failure in cancer. Mechanisms that have developed to guard cancer cells against anti-cancer drugs are major barriers to successful anti-cancer therapy. Therefore, the identification of novel mechanisms of cellular resistance holds the promise of leading to better treatments for cancer patients. In the present study, we used human MCF-7 breast adenocarcinoma cell line and its doxorubicin-resistant variant MCF-7/R to determine the role of alterations of DNA methylation of chemoresitance-related genes, such as multidrug resistance 1 (MDR1), glutathione-S-transferase (GSTpi), O(6)-methylguanine DNA methyltransferase (MGMT), and urokinase (Upa), in the development of drug resistance. The promoter regions of MDR1, GSTpi, MGMT, and Upa genes were highly methylated in MCF-7 cell line but not in its MCF-7/R drug resistant variant. The hypomethylated status of MDR1 gene was associated with overexpression of P-glycoprotein. We hypothesize that acquirement of doxorubicin resistance of MCF-7 cells is associated with DNA hypomethylation of the promoter regions of the MDR1, GSTpi, MGMT, and Upa genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16356834     DOI: 10.1016/j.canlet.2005.01.038

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  The epigenetics of breast cancer.

Authors:  Jovana Jovanovic; Jo Anders Rønneberg; Jörg Tost; Vessela Kristensen
Journal:  Mol Oncol       Date:  2010-04-29       Impact factor: 6.603

2.  Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL).

Authors:  Stefanie Kewitz-Hempel; Lars Kurch; Michaela Cepelova; Ines Volkmer; Axel Sauerbrey; Elke Conrad; Stephanie Knirsch; Gabriele Pöpperl; Daniel Steinbach; Ambros J Beer; Christof M Kramm; Carsten-Oliver Sahlmann; Bernhard Erdlenbruch; Wolf-Dieter Reinbold; Andreas Odparlik; Osama Sabri; Regine Kluge; Martin S Staege
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

Review 3.  Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip.

Authors:  Bumsoo Han; Chunjing Qu; Kinam Park; Stephen F Konieczny; Murray Korc
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

4.  Different modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 breast cancer cells.

Authors:  Jennifer Pasquier; Ludovic Galas; Céline Boulangé-Lecomte; Damien Rioult; Florence Bultelle; Pierre Magal; Glenn Webb; Frank Le Foll
Journal:  J Biol Chem       Date:  2012-01-06       Impact factor: 5.157

5.  High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance.

Authors:  Michael Boettcher; Frank Kischkel; Jörg D Hoheisel
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

6.  Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.

Authors:  Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Methods Mol Biol       Date:  2010

Review 7.  DNA methylation profiling in the clinic: applications and challenges.

Authors:  Holger Heyn; Manel Esteller
Journal:  Nat Rev Genet       Date:  2012-09-04       Impact factor: 53.242

8.  MicroRNA-mediated drug resistance in breast cancer.

Authors:  Kristy R Kutanzi; Olga V Yurchenko; Frederick A Beland; Vasyl' F Checkhun; Igor P Pogribny
Journal:  Clin Epigenetics       Date:  2011-06-27       Impact factor: 6.551

9.  The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression.

Authors:  L Lv; H Deng; Y Li; C Zhang; X Liu; Q Liu; D Zhang; L Wang; Y Pu; H Zhang; Y He; Y Wang; Y Yu; T Yu; J Zhu
Journal:  Cell Death Dis       Date:  2014-09-04       Impact factor: 8.469

Review 10.  Multidrug-resistant breast cancer: current perspectives.

Authors:  Heather L Martin; Laura Smith; Darren C Tomlinson
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.